Nonlinear model predictive control for dosing daily anticancer agents using a novel saturating-rate cell-cycle model

Computers in Biology and Medicine

Volumn 38, Issue 3, 2008, Pages 339-347

  Florian Jr , Jeffry A ^a   Eiseman, Julie L ^b,c   Parker, Robert S ^a  

^a University of Pittsburgh   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Biomedical systems; Cancer; Nonlinear model; Nonlinear model predictive control; Pharmacodynamics; Pharmacokinetics

Indexed keywords

NONLINEAR ANALYSIS; ONCOLOGY; PHARMACODYNAMICS;

BIOMEDICAL SYSTEMS; NONLINEAR MODEL; NONLINEAR MODEL PREDICTIVE CONTROL;

DRUG DOSAGE;

ANTINEOPLASTIC AGENT; HYDROXYTAMOXIFEN; NORTAMOXIFEN; TAMOXIFEN;

ALGORITHM; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; MODEL; NONHUMAN; NONLINEAR SYSTEM; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR VOLUME;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASMS; NONLINEAR DYNAMICS; TAMOXIFEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 39549096248     PISSN: 00104825     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.compbiomed.2007.12.003     Document Type: Article

References (24)

1. The American Cancer Society, Cancer facts & figures: 2007, URL: 〈http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf, 2007〉.
2. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 48 (1988) 7067-7071
3. Asachenkov A., Marchuk G., Mohler R., and Zuev S. Disease Dynamics (1994), Birkhäuser, Boston
4. Bajzer Z., Marušić M., and Vuk-Pavlović S. Conceptual frameworks for mathematical modeling of tumor growth dynamics. Math. Comput. Model. 23 6 (1996) 31-46
5. D.Z. D'Argenio, A. Schumitzky, ADAPT II Users Guide: Pharmacokinetic and Pharmacodynamic Systems Analysis Software, Biomedical Simulations Resource, University of Southern California, Los Angeles, CA, 1997.
6. Martin R.B. Optimal control drug scheduling of cancer chemotherapy. Automatica 28 (1992) 1113-1123
7. Panetta J.C., and Adam J. A mathematical model of cycle-specific chemotherapy. Math. Comput. Model. 22 2 (1995) 67-82
8. J.M. Harrold, J.L. Eiseman, W.C. Zamboni, R.S. Parker, Modeling of toxicity effects and nonlinearities in pharmacokinetics of 9-nitrocamptothecin in mice, in: AIChE Annual Meeting, Austin, TX, 2004.
9. Martin R., and Teo K.L. Optimal Control of Drug Administration in Cancer Chemotherapy (1994), World Scientific, River Edge, NJ
10. Ledzewicz U., and Schättler H. Optimal bang-bang controls for a two-compartment model in cancer chemotherapy. J. Optim. Theory Appl. 114 3 (2002) 609-637
11. Robinson S.P., Langan-Fahey S.M., Delinda A.J., and Jordan V.C. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab. Dispos. 19 1 (1991) 36-43
12. Conley B.A., Ramsland T.S., Sentz D.L., Wu S., Rosen D.M., Wollman M., and Eiseman J.L. Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice. Cancer Chemother. Pharmacol. 43 (1999) 183-197
13. Lopes N.M., Adams E.G., and Bhuyan B.K. Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol. 32 3 (1993) 235-242
14. Kozusko F., Chen P., Grant S.G., Day B.W., and Panetta J.C. A mathematical model of in vitro cancer cell growth and treatment with the antimitotic agent curacin A. Math. Biosci. 170 (2001) 1-16
15. J.A. Florian Jr., J.L. Eiseman, R.S. Parker. Approximating cancer tumor growth dynamics using cell-cycle models in series, in: AIChE Annual Meeting, paper 439ab, San Francisco, CA, 2003.
16. Lee G.S., Ryu K.S., Kim S.P., Namkoong S.E., and Han K.T. Multiparametric flow cytometric analysis in a breast cancer cell line (MCF-7). J. Obstet. Gynaecol. Res. 28 3 (2002) 141-148
17. Riesberg M., Kasper C., Reardon K.F., and Scheper T. Flow cytometry in biotechnology. Appl. Microbiol. Biotechnol. 56 (2001) 350-360
18. Akaike H. A Bayesian extension of the minimal AIC procedures of autoregressive model fitting. Biometrika 66 (1979) 237
19. Morari M., and Zafiriou E. Robust Process Control (1989), Prentice-Hall, Englewood Cliffs, NJ
20. M.J. Ellis, S.M. Swain, Steroid hormone therapies for cancer, in: B.A. Chabner, D.L. Longo (Eds.), Cancer Chemotherapy and Biotherapy: Principles and Practice, third ed., Lippincott Williams and Wilkins, 2001, pp. 103-113.
21. Martin E.A., Carthew P., White I.N., Heydon R.T., Gaskell M., Mauthe R.J., Turteltaub K.W., and Smith L.L. Invesitgation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen. Carcinogenesis 18 11 (1997) 2209-2215
22. Dayneka N.L., Gard V., and Jusko W.J. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21 4 (1993) 457-478
23. Morari M., and Ricker N.L. Model Predictive Control Toolbox (1994), The MathWorks, Inc., Natick, MA
24. J.A. Florian Jr., J.L. Eiseman, R.S. Parker, A nonlinear model predictive control algorithm for breast cancer treatment, in: Proceedings of the DYCOPS 7, Boston, MA, 2004.